Pfizer Inc (NYSE:PFE) reported Q1 earnings with adjusted EPS of 82 cents, down 33% YoY but above consensus of 54 cents. Sales were $14.9 billion, down 20%, yet above the $14.2 billion consensus. The decrease was attributed to lower Comirnaty and Paxlovid revenues and a $107 million foreign exchange impact. Analysts have mixed sentiments, with Goldman Sachs maintaining a Buy rating and a $31 price target, BMO Capital raising its target from $33 to $36 with an Outperform rating, and Bank of America Securities keeping a Neutral rating with a $35 target. Key product performances and future catalysts were highlighted, including Padcev, Prevnar, Vindaqel, and potential from Abrysvo. PFE shares rose 2.15% to $27.77.